Lung Neoplasms

"Lung Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the LUNG.

Descriptor ID	D008175
MeSH Number(s)	C04.588.894.797.520 C08.381.540 C08.785.520
Concept/Terms	Lung Neoplasms Lung Neoplasms Pulmonary Neoplasms Neoplasms, Lung Lung Neoplasm Neoplasm, Lung Neoplasms, Pulmonary Neoplasm, Pulmonary Pulmonary Neoplasm Lung Cancer Lung Cancer Cancer, Lung Cancers, Lung Lung Cancers Pulmonary Cancer Cancer, Pulmonary Cancers, Pulmonary Pulmonary Cancers Cancer of the Lung Cancer of Lung

Below are MeSH descriptors whose meaning is more general than "Lung Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Thoracic Neoplasms [C04.588.894]
Respiratory Tract Neoplasms [C04.588.894.797]
Lung Neoplasms [C04.588.894.797.520]
Respiratory Tract Diseases [C08]
Lung Diseases [C08.381]
Lung Neoplasms [C08.381.540]
Respiratory Tract Neoplasms [C08.785]
Lung Neoplasms [C08.785.520]

Below are MeSH descriptors whose meaning is related to "Lung Neoplasms".

Below are MeSH descriptors whose meaning is more specific than "Lung Neoplasms".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Lung Neoplasms" by people in this website by year, and whether "Lung Neoplasms" was a major or minor topic of these publications.

Bar chart showing 325 publications over 31 distinct years, with a maximum of 31 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	1	2	3
1993	2	0	2
1994	1	0	1
1995	4	0	4
1996	2	0	2
1997	1	0	1
1998	4	0	4
1999	3	0	3
2000	4	0	4
2001	1	2	3
2002	11	4	15
2003	8	3	11
2004	16	4	20
2005	12	3	15
2006	16	3	19
2007	15	2	17
2008	18	3	21
2009	22	3	25
2010	23	8	31
2011	16	2	18
2012	17	3	20
2013	8	1	9
2014	7	3	10
2015	8	3	11
2016	9	0	9
2017	13	2	15
2018	7	1	8
2019	3	1	4
2020	4	0	4
2021	9	0	9
2022	7	0	7

Below are the most recent publications written about "Lung Neoplasms" by people in Profiles.

Shusted CS, Evans NR, Kane GC, Juon HS, Barta JA. Analysis of Lung Cancer Screening by Race After USPSTF Expansion of Screening Eligibility in 2021. JAMA Netw Open. 2022 Jun 01; 5(6):e2217578.

View in: PubMed
Harel M, Lahav C, Jacob E, Dahan N, Sela I, Elon Y, Raveh Shoval S, Yahalom G, Kamer I, Zer A, Sharon O, Carbone DP, Dicker AP, Bar J, Shaked Y. Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade. J Immunother Cancer. 2022 Jun; 10(6).

View in: PubMed
DiCarlo M, Myers P, Daskalakis C, Shimada A, Hegarty S, Zeigler-Johnson C, Juon HS, Barta J, Myers RE. Outreach to primary care patients in lung cancer screening: A randomized controlled trial. Prev Med. 2022 Jun; 159:107069.

View in: PubMed
McIntire RK, Lewis E, Zeigler-Johnson C, Shusted C, Barta J, Juon HS, Keith SW, Klein G. Estimating Eligibility for Lung Cancer Screening by Neighborhood in Philadelphia Using Previous and Current USPSTF Guidelines. Popul Health Manag. 2022 04; 25(2):254-263.

View in: PubMed
Herskovitz E, Solomides C, Barta J, Evans N, Kane G. Detection of lung carcinoma arising from ground glass opacities (GGO) after 5 years - A retrospective review. Respir Med. 2022 05; 196:106803.

View in: PubMed
Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazeb AM, Hodi FS. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022 02; 23(2):279-291.

View in: PubMed
Barta JA. Variation in Adherence to Lung Cancer Screening Among Vulnerable Populations. Chest. 2022 01; 161(1):16-17.

View in: PubMed
Fisk JN, Mahal AR, Dornburg A, Gaffney SG, Aneja S, Contessa JN, Rimm D, Yu JB, Townsend JP. Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Lett. 2022 02 01; 526:346-351.

View in: PubMed
Vinogradskiy Y, Castillo R, Castillo E, Schubert L, Jones BL, Faught A, Gaspar LE, Kwak J, Bowles DW, Waxweiler T, Dougherty JM, Gao D, Stevens C, Miften M, Kavanagh B, Grills I, Rusthoven CG, Guerrero T. Results of a Multi-Institutional Phase 2 Clinical Trial for 4DCT-Ventilation Functional Avoidance Thoracic Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 03 15; 112(4):986-995.

View in: PubMed
Thangavel K, Lakshmikuttyamma A, Thangavel C, Shoyele SA. CD44-targeted, indocyanine green-paclitaxel-loaded human serum albumin nanoparticles for potential image-guided drug delivery. Colloids Surf B Biointerfaces. 2022 Jan; 209(Pt 1):112162.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement